TITLE

Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels

AUTHOR(S)
Vadi, Sonali; Agarwal, Manjusha
PUB. DATE
November 2017
SOURCE
Indian Journal of Critical Care Medicine;Nov2017, Vol. 21 Issue 11, p793
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The Food and Drug Administration has approved the use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for use in Type II diabetics. These are a relatively new addition to the armamentaria of diabetes management. Postmarketing surveillance is a witness to several side effects, a morbid one being ketoacidosis. Herein is discussed a scenario of a Type II diabetic who presented with substantial ketoacidosis without significant hyperglycemia. The absence of the customary precipitating factors and the presence of a recent introduction of canagliflozin, a SGLT-2 inhibitor to the diabetes prescription, hinted at the causal relationship. Of note, she had never experienced diabetic ketoacidosis in the past prior to commencement of SGLT-2 inhibitor therapy. As clinicians, we need to be aware of the treatment-emergent adverse effect of this relatively new class of diabetic treatment.
ACCESSION #
126249077

 

Related Articles

  • Canagliflozin.  // AHFS Consumer Medication Information;Oct2017, p1 

    Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is in a class of...

  • Canagliflozin.  // AHFS Consumer Medication Information;Oct2017, p1 

    Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is in a class of...

  • Canagliflozin.  // AHFS Consumer Medication Information;Oct2017, p1 

    Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is in a class of...

  • SGLT2 inhibitors: are they safe for patients?  // Nursing & Residential Care;Jun2016, Vol. 18 Issue 6, p299 

    No abstract available.

  • Sodium--Glucose Cotransporter 2 Inhibitors and euglycemic Diabetic Ketoacidosis: Metabolic Acidosis With a Twist. Jaberi, Aala; Seth, Bhavna; Steenkamp, Devin; Alexanian, Sara; Borkan, Steven C. // Clinical Diabetes;Fall2016, Vol. 34 Issue 4, p214 

    The article presents case study of a 47-year-old woman with a self-reported 11-year history of diabetes mellitus. It mentions that repeat arterial blood gas performed 12 hours after initial hospitalization confirmed progressive acidemia. It adds that initial absence of exogenous insulin...

  • Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus. Miller, Kevin; Miller, Eden M. // Journal of Family Practice;Dec2015 Supplement Hot Topics in Primary Care, pS54 

    The article offers information on the role of sodium-glucose cotransponders 2 (SGLT-2) and kidney on the treatment of type 2 diabetes mellitus (T2DM). Topics include several SGLT-2 inhibitors including dapagliflozin, canagliflozin, and empagliflozin, the safety and glycemic and nonglycemic...

  • Diabetic Ketoacidosis and Related Events in the Canaglif lozin Type 2 Diabetes Clinical Program. Erondu, Ngozi; Desai, Mehul; Ways, Kirk; Meininger, Gary // Diabetes Care;Sep2015, Vol. 38 Issue 9, p1680 

    OBJECTIVE This study assessed the incidence of serious adverse events of diabetic ketoacidosis (DKA) among patients with type 2 diabetes treated with canagliflozin. RESEARCH DESIGN AND METHODS All serious adverse events of DKA and related events (ketoacidosis, metabolic acidosis, and acidosis)...

  • Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity. Johnson, Mark D.; Louden, Calvert; De Jonghe, Sandra; Ways, Kirk; Mamidi, Rao N. V. S.; Proctor, James // Toxicologic Pathology;Jan2015, Vol. 43 Issue 1, p48 

    Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, has been developed for the treatment of adults with type 2 diabetes mellitus (T2DM). During the phase 3 program, treatment-related pheochromocytomas, renal tubular tumors, and testicular Leydig cell tumors were reported in the...

  • Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Devineni, Damayanthi; Polidori, David // Clinical Pharmacokinetics;Oct2015, Vol. 54 Issue 10, p1027 

    The sodium-glucose co-transporter 2 (SGLT2) inhibitors represent novel therapeutic approaches in the management of type 2 diabetes mellitus; they act on kidneys to decrease the renal threshold for glucose (RTG) and increase urinary glucose excretion (UGE). Canagliflozin is an orally active,...

  • Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. Hussey, Elizabeth K.; Kapur, Anita; O'Connor-Semmes, Robin; Tao, Wenli; Rafferty, Bryan; Polli, Joseph W.; James Jr., Charles D.; Dobbins, Robert L. // BMC Pharmacology & Toxicology;2013, Vol. 14 Issue 1, p1 

    Background: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics